Maraviroc-Containing PrEP Regimens Found to be Safe in Women
43  

Maraviroc-Containing PrEP Regimens Found to be Safe in Women

HIV infections continue to occur at a rate of >2 million globally each year with women accounting for a little over 50% of infections. Although the overall incidence of HIV infections in the United States has decreased in recent years, certain populations remain particularly vulnerable, including racial/ethnic ...

October 09, 2017
IAS 2017: Closing ceremony exposes Gilead Sciences
23  

IAS 2017: Closing ceremony exposes Gilead Sciences

Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” 9th International AIDS Conference on HIV Science in Paris (IAS 2017), drew to a close, in style. The community address delivered by Othoman Mellouk, during the final ceremony, exposed one of the key conference sponsors, ...

August 02, 2017
New results from Flash! PrEP in Europe released at IAS 2017
28  

New results from Flash! PrEP in Europe released at IAS 2017

AIDES and PLUS announced to conference attendees from the world over results from the biggest European survey ever to be conducted regarding knowledge, interest and utilisation of PrEP, Flash! PrEP in Europe. This presentation revealed the principal barriers, both individual and structural, regarding access to this ...

July 31, 2017
PrEP now included on the WHO Essential Medicines List
18  

PrEP now included on the WHO Essential Medicines List

Key HIV drugs added to the list of medicines critical to public health, including tenofovir for HIV prevention, and dolutegravir. Earlier this month, the World Health Organization (WHO) updated their list of medicines deemed ‘essential’ as part of a well-functioning health system. That is, the drugs ...

June 23, 2017